Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia

Tino Schenk, Weihsu Claire Chen, Stefanie Göllner, Louise Howell, Liqing Jin, Katja Hebestreit, Hans Ulrich Klein, Andreea C. Popescu, Alan Burnett, Ken Mills, Robert A Casero, Laurence Marton, Patrick Woster, Mark D. Minden, Martin Dugas, Jean C Y Wang, John E. Dick, Carsten Müller-Tidow, Kevin Petrie, Arthur Zelent

Research output: Contribution to journalArticle

Abstract

Acute promyelocytic leukemia (APL), a cytogenetically distinct subtype of acute myeloid leukemia (AML), characterized by the t(15;17)-associated PML-RARA fusion, has been successfully treated with therapy utilizing all-trans-retinoic acid (ATRA) to differentiate leukemic blasts. However, among patients with non-APL AML, ATRA-based treatment has not been effective. Here we show that, through epigenetic reprogramming, inhibitors of lysine-specific demethylase 1 (LSD1, also called KDM1A), including tranylcypromine (TCP), unlocked the ATRA-driven therapeutic response in non-APL AML. LSD1 inhibition did not lead to a large-scale increase in histone 3 Lys4 dimethylation (H3K4 me2) across the genome, but it did increase H3K4 me2 and expression of myeloid-differentiation-associated genes. Notably, treatment with ATRA plus TCP markedly diminished the engraftment of primary human AML cells in vivo in nonobese diabetic (NOD)-severe combined immunodeficient (SCID) mice, suggesting that ATRA in combination with TCP may target leukemia-initiating cells. Furthermore, initiation of ATRA plus TCP treatment 15 d after engraftment of human AML cells in NOD-SCID γ (with interleukin-2 (IL-2) receptor γ chain deficiency) mice also revealed the ATRA plus TCP drug combination to have a potent anti-leukemic effect that was superior to treatment with either drug alone. These data identify LSD1 as a therapeutic target and strongly suggest that it may contribute to AML pathogenesis by inhibiting the normal pro-differentiative function of ATRA, paving the way for new combinatorial therapies for AML.

Original languageEnglish (US)
Pages (from-to)605-611
Number of pages7
JournalNature Medicine
Volume18
Issue number4
DOIs
StatePublished - Apr 2012

Fingerprint

Tretinoin
Acute Myeloid Leukemia
Tranylcypromine
Myeloid Cells
Therapeutics
Genes
Acute Promyelocytic Leukemia
SCID Mice
Interleukin-2 Receptors
Drug Combinations
Epigenomics
Histones
Lysine
Leukemia
Fusion reactions
Genome
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Schenk, T., Chen, W. C., Göllner, S., Howell, L., Jin, L., Hebestreit, K., ... Zelent, A. (2012). Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nature Medicine, 18(4), 605-611. https://doi.org/10.1038/nm.2661

Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. / Schenk, Tino; Chen, Weihsu Claire; Göllner, Stefanie; Howell, Louise; Jin, Liqing; Hebestreit, Katja; Klein, Hans Ulrich; Popescu, Andreea C.; Burnett, Alan; Mills, Ken; Casero, Robert A; Marton, Laurence; Woster, Patrick; Minden, Mark D.; Dugas, Martin; Wang, Jean C Y; Dick, John E.; Müller-Tidow, Carsten; Petrie, Kevin; Zelent, Arthur.

In: Nature Medicine, Vol. 18, No. 4, 04.2012, p. 605-611.

Research output: Contribution to journalArticle

Schenk, T, Chen, WC, Göllner, S, Howell, L, Jin, L, Hebestreit, K, Klein, HU, Popescu, AC, Burnett, A, Mills, K, Casero, RA, Marton, L, Woster, P, Minden, MD, Dugas, M, Wang, JCY, Dick, JE, Müller-Tidow, C, Petrie, K & Zelent, A 2012, 'Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia', Nature Medicine, vol. 18, no. 4, pp. 605-611. https://doi.org/10.1038/nm.2661
Schenk, Tino ; Chen, Weihsu Claire ; Göllner, Stefanie ; Howell, Louise ; Jin, Liqing ; Hebestreit, Katja ; Klein, Hans Ulrich ; Popescu, Andreea C. ; Burnett, Alan ; Mills, Ken ; Casero, Robert A ; Marton, Laurence ; Woster, Patrick ; Minden, Mark D. ; Dugas, Martin ; Wang, Jean C Y ; Dick, John E. ; Müller-Tidow, Carsten ; Petrie, Kevin ; Zelent, Arthur. / Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. In: Nature Medicine. 2012 ; Vol. 18, No. 4. pp. 605-611.
@article{1e014a061f7e417fab2652830866af04,
title = "Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia",
abstract = "Acute promyelocytic leukemia (APL), a cytogenetically distinct subtype of acute myeloid leukemia (AML), characterized by the t(15;17)-associated PML-RARA fusion, has been successfully treated with therapy utilizing all-trans-retinoic acid (ATRA) to differentiate leukemic blasts. However, among patients with non-APL AML, ATRA-based treatment has not been effective. Here we show that, through epigenetic reprogramming, inhibitors of lysine-specific demethylase 1 (LSD1, also called KDM1A), including tranylcypromine (TCP), unlocked the ATRA-driven therapeutic response in non-APL AML. LSD1 inhibition did not lead to a large-scale increase in histone 3 Lys4 dimethylation (H3K4 me2) across the genome, but it did increase H3K4 me2 and expression of myeloid-differentiation-associated genes. Notably, treatment with ATRA plus TCP markedly diminished the engraftment of primary human AML cells in vivo in nonobese diabetic (NOD)-severe combined immunodeficient (SCID) mice, suggesting that ATRA in combination with TCP may target leukemia-initiating cells. Furthermore, initiation of ATRA plus TCP treatment 15 d after engraftment of human AML cells in NOD-SCID γ (with interleukin-2 (IL-2) receptor γ chain deficiency) mice also revealed the ATRA plus TCP drug combination to have a potent anti-leukemic effect that was superior to treatment with either drug alone. These data identify LSD1 as a therapeutic target and strongly suggest that it may contribute to AML pathogenesis by inhibiting the normal pro-differentiative function of ATRA, paving the way for new combinatorial therapies for AML.",
author = "Tino Schenk and Chen, {Weihsu Claire} and Stefanie G{\"o}llner and Louise Howell and Liqing Jin and Katja Hebestreit and Klein, {Hans Ulrich} and Popescu, {Andreea C.} and Alan Burnett and Ken Mills and Casero, {Robert A} and Laurence Marton and Patrick Woster and Minden, {Mark D.} and Martin Dugas and Wang, {Jean C Y} and Dick, {John E.} and Carsten M{\"u}ller-Tidow and Kevin Petrie and Arthur Zelent",
year = "2012",
month = "4",
doi = "10.1038/nm.2661",
language = "English (US)",
volume = "18",
pages = "605--611",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia

AU - Schenk, Tino

AU - Chen, Weihsu Claire

AU - Göllner, Stefanie

AU - Howell, Louise

AU - Jin, Liqing

AU - Hebestreit, Katja

AU - Klein, Hans Ulrich

AU - Popescu, Andreea C.

AU - Burnett, Alan

AU - Mills, Ken

AU - Casero, Robert A

AU - Marton, Laurence

AU - Woster, Patrick

AU - Minden, Mark D.

AU - Dugas, Martin

AU - Wang, Jean C Y

AU - Dick, John E.

AU - Müller-Tidow, Carsten

AU - Petrie, Kevin

AU - Zelent, Arthur

PY - 2012/4

Y1 - 2012/4

N2 - Acute promyelocytic leukemia (APL), a cytogenetically distinct subtype of acute myeloid leukemia (AML), characterized by the t(15;17)-associated PML-RARA fusion, has been successfully treated with therapy utilizing all-trans-retinoic acid (ATRA) to differentiate leukemic blasts. However, among patients with non-APL AML, ATRA-based treatment has not been effective. Here we show that, through epigenetic reprogramming, inhibitors of lysine-specific demethylase 1 (LSD1, also called KDM1A), including tranylcypromine (TCP), unlocked the ATRA-driven therapeutic response in non-APL AML. LSD1 inhibition did not lead to a large-scale increase in histone 3 Lys4 dimethylation (H3K4 me2) across the genome, but it did increase H3K4 me2 and expression of myeloid-differentiation-associated genes. Notably, treatment with ATRA plus TCP markedly diminished the engraftment of primary human AML cells in vivo in nonobese diabetic (NOD)-severe combined immunodeficient (SCID) mice, suggesting that ATRA in combination with TCP may target leukemia-initiating cells. Furthermore, initiation of ATRA plus TCP treatment 15 d after engraftment of human AML cells in NOD-SCID γ (with interleukin-2 (IL-2) receptor γ chain deficiency) mice also revealed the ATRA plus TCP drug combination to have a potent anti-leukemic effect that was superior to treatment with either drug alone. These data identify LSD1 as a therapeutic target and strongly suggest that it may contribute to AML pathogenesis by inhibiting the normal pro-differentiative function of ATRA, paving the way for new combinatorial therapies for AML.

AB - Acute promyelocytic leukemia (APL), a cytogenetically distinct subtype of acute myeloid leukemia (AML), characterized by the t(15;17)-associated PML-RARA fusion, has been successfully treated with therapy utilizing all-trans-retinoic acid (ATRA) to differentiate leukemic blasts. However, among patients with non-APL AML, ATRA-based treatment has not been effective. Here we show that, through epigenetic reprogramming, inhibitors of lysine-specific demethylase 1 (LSD1, also called KDM1A), including tranylcypromine (TCP), unlocked the ATRA-driven therapeutic response in non-APL AML. LSD1 inhibition did not lead to a large-scale increase in histone 3 Lys4 dimethylation (H3K4 me2) across the genome, but it did increase H3K4 me2 and expression of myeloid-differentiation-associated genes. Notably, treatment with ATRA plus TCP markedly diminished the engraftment of primary human AML cells in vivo in nonobese diabetic (NOD)-severe combined immunodeficient (SCID) mice, suggesting that ATRA in combination with TCP may target leukemia-initiating cells. Furthermore, initiation of ATRA plus TCP treatment 15 d after engraftment of human AML cells in NOD-SCID γ (with interleukin-2 (IL-2) receptor γ chain deficiency) mice also revealed the ATRA plus TCP drug combination to have a potent anti-leukemic effect that was superior to treatment with either drug alone. These data identify LSD1 as a therapeutic target and strongly suggest that it may contribute to AML pathogenesis by inhibiting the normal pro-differentiative function of ATRA, paving the way for new combinatorial therapies for AML.

UR - http://www.scopus.com/inward/record.url?scp=84862777766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862777766&partnerID=8YFLogxK

U2 - 10.1038/nm.2661

DO - 10.1038/nm.2661

M3 - Article

C2 - 22406747

AN - SCOPUS:84862777766

VL - 18

SP - 605

EP - 611

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 4

ER -